Login
Search
Search
0 Dates
2026
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
CPC 2026
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Transcatheter aortic valve implantation in a centre without a cardiac surgery department but with immediate onsite surgical backup: first report on safety and feasibility
Session:
Sessão de Posters 31 - Intervenção transcateter na válvula aórtica: acesso, futilidade e anatomia complexa
Speaker:
Hélder Pereira
Congress:
CPC 2026
Topic:
---
Theme:
---
Subtheme:
---
Session Type:
Posters Eletrónicos
FP Number:
---
Authors:
Ana Rita F. Pereira; Rita Calé; Rui Campante Teles; Tiago Nolasco; Ana Cristina Martins; João Brito; Paulo Oliveira; Hugo Vilela; Pedro Tiago Santos; Rafael Maniés Pereira; Hélder Pereira
Abstract
<p style="text-align:justify"><span style="font-size:medium"><span style="font-family:Aptos,sans-serif"><span style="color:#000000"><strong>Introduction: </strong>Transcatheter aortic valve implantation (TAVI) is an established alternative to surgical replacement for severe aortic stenosis. Although its safety and efficacy are well supported, current guidelines recommend performing TAVI only in centres with on-site cardiac surgery. Growing experience, device improvements, proctoring and the development of structured Heart Teams may enable safe expansion of TAVI to non-surgical centres with immediate surgical standby, potentially reducing procedural waiting times.</span></span></span></p> <p style="text-align:justify"> </p> <p style="text-align:justify"><span style="font-size:medium"><span style="font-family:Aptos,sans-serif"><span style="color:#000000"><strong>Purpose: </strong>To evaluate procedural and short-term outcomes of TAVI performed in a non–cardiac surgery centre with on-site surgical backup.</span></span></span></p> <p style="text-align:justify"> </p> <p style="text-align:justify"><span style="font-size:medium"><span style="font-family:Aptos,sans-serif"><span style="color:#000000"><strong>Methods: </strong>Prospective, single-centre, observational study including a total of 53 consecutive patients (mean age 84 ± 4 years, 55% female, median EuroSCORE II 2.5 [IQR 1.9–3.2]) who underwent TAVI between June/2024 and June/2025 at a non-surgical cardiac centre. The program was developed in partnership with a tertiary centre with high-volume structural interventions and cardiac surgery, operating under a structured collaboration model that includes regular Heart Team meetings, operator training, on-site proctoring, and surgical standby. Primary endpoints were technical success and 30-day device success. Secondary endpoints included 30-day mortality, stroke, major vascular complications, moderate/severe paravalvular leak (PVL), and new permanent pacemaker implantation. Endpoints followed Valve Academic Research Consortium-3 (VARC-3) definitions.</span></span></span></p> <p style="text-align:justify"> </p> <p style="text-align:justify"><span style="font-size:medium"><span style="font-family:Aptos,sans-serif"><span style="color:#000000"><strong>Results: </strong>Femoral access was used in 98.1%. Supra-valvular self-expanding valves (SEV) were implanted in 92.5% (88% non-resheathable, 12% resheathable) and balloon-expandable (BEV) in 7.5%. Technical and 30-day device success were achieved in 98.1% and 96.2%, respectively. Thirty-day mortality was 1.9%; stroke 3.8%; major vascular complications 1.9%. New permanent pacemaker implantation occurred in 11.3%. There were no intra-procedural deaths, emergency conversions, valve embolization, coronary obstruction or moderate/severe PVL.</span></span></span></p> <p style="text-align:justify"> </p> <p style="text-align:justify"><span style="font-size:medium"><span style="font-family:Aptos,sans-serif"><span style="color:#000000"><strong>Conclusions: </strong>Our findings support the feasibility and safety of TAVI procedures performed in a centre without a dedicated cardiac surgery department, provided that procedures are supported by structured collaboration, operator training, proctoring, and local on-site surgical standby. Further studies and long-term data are warranted to validate that these outcomes are consistent with those of pivotal TAVI trials.</span></span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site